SEC Form 4 · accession 0001209191-15-008046
Revance Therapeutics, Inc. · RVNC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Curtis Ruegg
Officer — EVP R&D and Tech Operations
Period of report
Jan 28, 2015
Accepted (ET)
Jan 30, 2015 · 7:10 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479290
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 28, 2015 | A | 5,231 | $0.00 | A | 19,337 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $16.23 | Jan 28, 2015 | A | 29,644 | A | — | Jan 27, 2025 | Common Stock | 29,644 | 29,644 | D |
Explanation of responses
- F1The shares subject to the Restricted Stock Award shall vest in three (3) equal annual installments from January 28, 2015, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan (the "Plan")) on each vesting date.
- F2The shares subject to the Stock Option Grant shall vest in forty-eight (48) equal monthly installments from January 28, 2015, subject to Reporting Person's Continuous Service (as defined in the Plan) on each vesting date.